Literature DB >> 31565588

Uremic Pruritus: Prevalence and Impact on Quality of Life and Depressive Symptoms in Hemodialysis Patients.

Muhammad Zubair Satti1, Danish Arshad2, Hassan Javed2, Ahmad Shahroz2, Zeeshan Tahir2, Mian Muhammad Hassan Ahmed3, Arslan Kareem3.   

Abstract

Background End-stage renal disease (ESRD) is a major public health problem with many associated symptoms. Uremic pruritus (UP) develops in 40% of patients on hemodialysis and has major effects on the patient's life. It is also an independent risk factor for increased mortality, and its psychiatric implications remain poorly characterized in our local setup, where it tends to be underdiagnosed and undertreated. Objectives and rationale The study aims to report the prevalence of uremic pruritus in our study population and associate it with various patient parameters, which may define a subset of patients at high risk for this pruritus. We also assess the effects of uremic pruritus on the patient's quality of life (by using the Dermatology Life Quality Index; DLQI) and depressive symptoms (by using the Public Health Questionnaire; PHQ-9). Materials and methods It was a descriptive, cross-sectional study conducted in the nephrology unit of the multi-organ failure (MOF) center of the Holy Family Hospital (HFH), Rawalpindi, Pakistan, from February 2019 to June 2019, during which 173 male patients on hemodialysis were selected. Informed consent was taken from patients and other skin-related causes of pruritis were excluded. Uremic pruritus was defined as pruritis lasting for at least three months after the onset of ESRD. The 5-D, PHQ-9, and DLQI questionnaires were used to assess pruritis, depressive symptoms, and quality of life, respectively. Their Cronbach's Alpha values for 73 responses were 0.83, 0.81, and 0.71, respectively. The descriptive analysis was performed using SPSS v23.0 (IBM Corp, Armonk, NY, US). Spearman's rank-order correlation, independent samples t-test, and one-way analysis of variance (ANOVA) were used to analyze study variables. Results The prevalence of uremic pruritus was 49.1%, with many patients having generalized itching. Unemployment and longer disease duration predisposed the patients towards uremic pruritus, as the mean 5-D score in this subset were greater (p<0.05 in the independent samples t-test). The results of one-way ANOVA were significant (p<0.05), indicating higher 5-D scores in worsening categories of depressive symptoms and quality of life. Spearman's correlation matrix showed that 5-D, PHQ-9, and DLQI scores were strongly correlated with each other. Conclusions The prevalence of uremic pruritus among male hemodialysis patients is high, at 49.1%. It significantly contributes to depressive symptoms and a lower quality of life, which are associated with worse prognosis in hemodialysis patients. Thus, a clinician must keep in mind the psychiatric implications of uremic pruritus and treat it effectively to optimize the patient's medical care.
Copyright © 2019, Satti et al.

Entities:  

Keywords:  depression; end stage renal disease; quality of life; uremic pruritus

Year:  2019        PMID: 31565588      PMCID: PMC6758963          DOI: 10.7759/cureus.5178

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

End-stage renal disease (ESRD), which mandates dialysis, is a burgeoning public health problem with an ever-increasing prevalence throughout the world. An estimated 200 million people are reported to suffer from chronic kidney disease (CKD) and many of these patients eventually progress to ESRD [1-3]. In recent times, many efforts have been made to improve the survival of hemodialysis patients with end-stage renal disease. While hemodialysis has improved the survival rates, concerns regarding a reduction in quality of life (QoL) due to ESRD are worrisome and have been reported by numerous studies [4-5]. Thus, the need for an improvement in the quality of life in chronic hemodialysis patients with end-stage renal disease has been strongly emphasized. The lower QoL in ESRD is because of many associated life-limiting symptoms such as pruritus. Pruritus associated with ESRD (called uremic pruritus) is an irritating sensation of the skin that causes a desire to scratch. The prevalence of uremic pruritus is reported to vary, affecting around one-third of these patients [6]. Moreover, unlike other symptoms of ESRD, dialysis only has the mild effect of reducing pruritus, and many patients undergoing hemodialysis complain of varying degree of pruritus [7-8]. The extent and severity of uremic pruritus vary between patients. In some patients, it is extensive and persistent while in others, it may be short-lived and localized. Severe uremic pruritus was found to be an independent risk factor of mortality in ESRD patients [9-10]. The exact pathogenesis of uremic pruritus remains unclear, but it is postulated to be multifactorial [11]. Histamine, parathormone, and electrolyte derangements (particularly of calcium and magnesium salts) have been implicated in pruritus and newer hypotheses focus on micro-inflammation and opioid-receptor malfunctions as possible causes of ESRD-associated pruritus [11-12]. There are a variety of therapeutic interventions that are useful in the treatment or reduction of the severity of uremic pruritus, such as correction of calcium and phosphorus levels, phototherapy, and acupuncture, with varying results [13]. Another CKD-associated condition is depressive symptoms with a high reported prevalence in this population [14]. It is associated with poor adherence to dialysis, medications, nutrition, poor quality of life, and higher mortality [14]. We hypothesize that one of many factors responsible for depressive symptoms may be uremic pruritus, as it lowers QoL, makes social interaction difficult, and leads to a continuous nagging sensation of itching along with disturbed sleep. All these possible effects of this pruritis have been linked to depressive symptoms in many studies [15]. However, we found no such study in our local set-up that considers the psychiatric implications of uremic pruritus. Thus, chronic pruritus represents a serious public health concern that must be adequately addressed by clinicians. Despite the high prevalence and life-changing effects of pruritus in hemodialysis patients, the assessment of its effects on the lives of patients remains poorly characterized, especially in our local settings. Therefore, the goal of this study is to determine the prevalence and impact of uremic pruritus on the patient’s quality of life and to analyze whether it is associated with depressive symptoms in this population. We also assess various patient-related factors for their association with uremic pruritus. The results will help the local physicians to inquire and treat the pruritus in these patients so that their QoL can be improved. Furthermore, the results may also identify a subset of the dialysis population at high risk for uremic pruritus.

Materials and methods

Study design It was a descriptive, cross-sectional study conducted in the nephrology unit of the multi-organ failure (MOF) center of Holy Family Hospital (HFH), Rawalpindi, Pakistan, from February 2019 to June 2019. The study population included patients with ESRD on hemodialysis (for at least three months). Randomization was performed by systemic sampling in which patients coming for dialysis were numbered randomly, and each patient with an even number was selected for the study. The mini-mental state examination (MMSE) was used to evaluate the mental state of the patients, and those with a score of less than 19 were excluded from the study, as they may not be able to deliver reliable answers. It was ensured that the itch reported by the patients was due to uremic pruritis and not because of related skin conditions, such as psoriasis, eczema, or dermatitis, by excluding them one by one. Uremic pruritus was defined as pruritus lasting for at least three months after the onset of ESRD. However, to ensure accurate recall, questions about the intensity and severity of the pruritus were asked, considering only the last two weeks according to the 5-D itch scale. During the study period, 173 male patients were interviewed at the bedside by trained investigators after obtaining informed consent. Only male patients were selected for the study because of their easy availability in the dialysis center of our hospital. Moreover, since males have a greater predisposition towards rapid progression to ESRD and earlier hemodialysis as compared to females, it is imperative to see the factors that affect their QoL [1]. Also, due to cultural norms in Pakistan, women tend to undergo peritoneal dialysis at home, which limits the accessibility to this subset of the population. Questionnaires used Multiple questionnaires were employed for the collection of data, including: 1) 5-D Itch Scale To assess pruritus in the population, we used the 5-D itch scale, which inquires five dimensions related to pruritus: duration, degree, direction, associated disability, and distribution of pruritus. The categories of the 5-D itch scale have been equivalated with the numeric rating scale (NRS) by a study that concludes that for the 5-D scale, scores of less than 9 mean no pruritus, 9-11 indicate mild, 12-17 indicate moderate, and 18-21 indicate severe pruritus [16]. 2) Public Health Questionnaire-9 To assess depression, the Urdu version of the Public Health Questionnaire-9 (PHQ-9) was used, which is a nine-item scale with a scoring range of 0-27. Scores from 0-4 correspond to no depression, 5-9 show mild, 10-14 moderate, 15-19 to moderately severe, while scores above 20 are consistent with severe depression [17]. 3) Dermatology Life Quality Index (DLQI) The self-explanatory DLQI questionnaire was used to observe the effects of pruritus on a patient’s quality of life. Its reliability for the purpose is also well-established by many studies [18]. A score of 0-1 means there is no effect of pruritis on the patient’s life, 2-5 indicates small, 6-10 indicates moderate, 11-20 indicates large, and 21-30 means very large and severe limiting effects on the patient’s life due to the associated pruritis. Cronbach's alpha of the questionnaires The inter-scale reliability of the questionnaire in our study population was assessed by calculating Cronbach's alpha for the first 73 responses. It was 0.83 for the 5-D itch scale, 0.81 for PHQ-9, and 0.71 for DLQI, indicating the high reliability of these questionnaires in our study population. Statistical analysis A total of 173 male patients constituted our final sample for an alpha value of 0.05 and power of study at 80%. A descriptive analysis of the study variables was performed using SPSS v23.0 (IBM Corp, Armonk, NY, US). The normality of the data was checked by the Shapiro Wilk test. We assessed the population parameters that were significantly associated with the 5-D itch scale by the independent samples t-test (where means were compared) and Spearman’s rank-order correlation (where continuous variables were available). Then, we analyzed the difference in mean 5-D itch scores regarding different categories of PHQ-9 and DLQI questionnaires by one-way analysis of variance (ANOVA). Further, since the scores were non-normally distributed, continuous variables, a correlation matrix was drawn using Spearman’s rank-order correlation to observe the correlation between the 5-D, PHQ-9, and DLQI scores. A p-value of less than 0.05 was considered statistically significant.

Results

Population demographics and parameters are provided in Table 1. The table also shows the parameters that are significantly associated with the 5-D itch scale by appropriate tests of significance.
Table 1

Demographic details and their association with the 5-D score

ParametersTest of significance with 5-D scoresp-values
Employment (n=173)Mean 5-D scores
Employed=116 (67.1%)9.2±1.7Independent samples t-testp=0.01
Unemployed=57 (32.9%)11.8±3,2
Session timing (n=173) 
Morning session=68 (39.3%)10.7±2.5Independent samples t-testp=0.53
Evening session=105 (60.7%)11.1±2.9
Age=39.4±4.3Spearman’s correlation r=0.14p=0.45
Disease years=5.9±2.8Spearman’s correlation r=0.64p=0.002
Hemodialysis years=2.1±1.2Spearman’s correlation r=0.12p=0.63
Table 2 shows the details of pruritus in the population. The distribution of pruritus among patients was significant for generalized pruritis.
Table 2

Details of pruritus in the population

DLQI: Dermatology Life Quality Index; PHQ-9: Public Health Questionnaire

ParameterNumber of patients
Mean 5-D score of the population (n=173)10.9±2.3
Pruritus intensity (n=173)
No pruritus88 (50.9%)
Mild47 (27.2%)
Moderate29 (16.8%)
Severe9 (5.2%)
Distribution of pruritus among 85 pruritic patients
Arms13 (15.3%)
Legs12 (14.1%)
Face11 (12.9%)
Trunk and back15 (17.6%)
Generalized (2 or more areas)34 (40.0%)
Mean DLQI score (n=85)9.8±1.7
Mean PHQ-9 score (n=173)12.2±2.9
Chi-square test for the distribution of pruritis was significant at p=0.02

Details of pruritus in the population

DLQI: Dermatology Life Quality Index; PHQ-9: Public Health Questionnaire Table 3 shows the distribution of 5-D scores in different categories of PHQ-9 and DLQI scores. The scores increase in higher degrees of depressive symptoms or lifestyle limitation, which was statistically significant, as means scores had p<0.05 for both indices when calculated by one-way analysis of variance (one-way ANOVA).
Table 3

5-D scores in different categories of PHQ-9 and DLQI scores

DLQI: Dermatology Life Quality Index; PHQ-9: Public Health Questionnaire; ANOVA: Analysis of Variance

ParameterPHQ-9 categories (n=173)One-way ANOVA (p-value)
No depressionMildModerateModerately severeSevere
Number of patients106 (61.3%)31 (17.9%)21 (12.1%)12 (6.9%)3 (1.7%)
5-D itch score8.1±1.810.7±2.513.1±3.717.6±4.819.5±5.80.001
DLQI categories (n=85)
ParameterNo effectSmallModerateLargeExtremely largeOne-way ANOVA (p-value)
Number of patients16 (18.8%)20 (23.5%)29 (34.1%)14 (16.5%)6 (7.1%)
5-D itch score10.2±2.712.7±3.215.1±4.718.3±4.920.2±5.60.005

5-D scores in different categories of PHQ-9 and DLQI scores

DLQI: Dermatology Life Quality Index; PHQ-9: Public Health Questionnaire; ANOVA: Analysis of Variance Table 4 shows the correlation matrix between the 5-D, PHQ-9, and DLQI scores drawn by using Spearman’s rank-order correlation.
Table 4

Correlation matrix by Spearman's correlation

DLQI: Dermatology Life Quality Index; PHQ-9: Public Health Questionnaire

ParameterSpearman’s coefficient (r) and p-values
5-D itch scoreDLQI scoresPHQ-9 scores
5-D itch score1r=0.78, p <0.000r=0.66, p=0.01
DLQI scoresr=0.78, p <0.0001r=0.69, p=0.01
PHQ-9 scoresr=0.66, p=0.01r=0.69, p=0.011

Correlation matrix by Spearman's correlation

DLQI: Dermatology Life Quality Index; PHQ-9: Public Health Questionnaire

Discussion

The results of our study provide important insights into the problem of uremic pruritus among male hemodialysis patients. We found a prevalence of 49.1% (85 out of 173) regarding uremic pruritus, where the majority of the patients had mild to moderate degrees of pruritus as classified by the 5-D itch scale. The prevalence is similar to what other studies reported and indicates the widespread occurrence of uremic pruritus in dialysis patients [19-21]. Many patients (40%) reported generalized pruritic itching involving their entire bodies, which were characteristically more severe on the face and back. Other patients (60%) said that itching was localized and the most common location was the trunk and back for localized itching sensation. Similar results were reported by another study, which also found that in many patients, uremic pruritus presented as generalized itching and discomfort among patients [7]. When we analyzed the association between uremic pruritus and patient parameters, we found some important associations with uremic pruritus. In our study, those males who were employed had significantly lower 5-D scores than unemployed males (p-value of t-test was 0.01). As employment keeps a person busy, the lower 5-D scores might relate to the psychological masking effect of a regular job, which may itself suppress the desire to itch. We also found that disease years had a moderate correlation with 5-D scores, at significant p-values. Since it is the decline in kidney function that contributes to uremic pruritus, more disease years will automatically translate to worsening kidney function and, hence, higher 5-D scores. The results are important and agree with another study conducted in Pakistan [22]. Our study indicates that age, hemodialysis years, and timing of dialysis session had no significant association with 5-D scores, which is in agreement with previous studies [20,23]. Next, we assess the distribution of 5-D scores in different categories of depression and lifestyle limitation. To have a good outlook of the effects of uremic pruritus, only the DLQI questionnaires of patients who had at least nine points in the 5-D scale were included in the analysis. This allowed us to measure QoL, particularly in association with uremic pruritus. No such modification was made for depressive symptoms because they have multifactorial causation. Our results indicate that depressive symptoms and lifestyle limitations are strongly correlated with 5-D scores and a significant ANOVA test concludes that higher degrees of PHQ-9 and DLQI have higher mean 5-D scores. A patient with higher 5-D scores, indicating worsening pruritus also suffers from a greater magnitude of depressive symptoms and lower QoL proportionately. This has an important clinical manifestation because a clinician must tend to treat pruritus in these patients by medical or non-medical measures instead of just waiting to see if it resolves with hemodialysis. Lower QoL and depressive symptoms have been linked to a lack of motivation, poor compliance with medical therapy, and higher mortality rates among hemodialysis patients [24]. Since both are significantly correlated with 5-D scores, a physician must always keep in mind the appearance of pruritus and its depressive effects in all patients of ESRD. These findings agree with many previous studies and underscore the grave consequences of untreated pruritis in hemodialysis patients [23,25-26]. Uremic pruritus generally remains undertreated in many dialysis patients and only routine antihistamines are prescribed, especially in developing countries [24,27]. By highlighting the importance of uremic pruritus in association with depressive symptoms and lower quality of life, our study calls for immediate and effective treatment of pruritis in hemodialysis patients so that their medical care is optimized and quality of life is improved.

Conclusions

The prevalence of uremic pruritus among male patients on hemodialysis was 49.1%. The pruritus was generalized in many patients, and unemployed males with longer disease years were more prone to suffer from this pruritus. The 5-D score was strongly correlated with depressive symptoms and lower QoL among subjects, indicating that uremic pruritus contributes to depression and lifestyle limitations. These findings mandate the need for the immediate and effective treatment of uremic pruritus among dialysis patients so that their mortality is reduced and quality of life is enhanced.
  25 in total

Review 1.  Uremic pruritus pathogenesis, revisited.

Authors:  Enas A S Attia; Ahmed A Hassan
Journal:  Arab J Nephrol Transplant       Date:  2014-05

Review 2.  10 years experience of the Dermatology Life Quality Index (DLQI).

Authors:  Victoria Lewis; Andrew Y Finlay
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

Review 3.  Addressing the global burden of chronic kidney disease through clinical and translational research.

Authors:  Akinlolu Ojo
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  Uraemic pruritus markedly affects the quality of life and depressive symptoms in haemodialysis patients with end-stage renal disease.

Authors:  Joanna Suseł; Aleksandra Batycka-Baran; Adam Reich; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2014-05       Impact factor: 4.437

Review 5.  Uraemic pruritus: clinical characteristics, pathophysiology and treatment.

Authors:  Lucio Manenti; Pius Tansinda; Augusto Vaglio
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Impact of Uraemic Pruritus on Quality of Life among End Stage Renal Disease Patients on Dialysis.

Authors:  Mohamed K Ibrahim; Ahmed R Elshahid; Tarek Z El Baz; Raed M Elazab; Sara A Elhoseiny; Mohamed L Elsaie
Journal:  J Clin Diagn Res       Date:  2016-03-01

7.  Uremic pruritus and associated factors in hemodialysis patients: A multi-center study.

Authors:  Nurten Ozen; Fatma Ilknur Cinar; Dilek Askin; Dilek Mut
Journal:  Kidney Res Clin Pract       Date:  2018-06-30

Review 8.  Prevalence of chronic kidney disease-associated pruritus among adult dialysis patients: A meta-analysis of cross-sectional studies.

Authors:  Xinmiao Hu; Yan Sang; Mei Yang; Xue Chen; Wenjuan Tang
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

9.  The impact on quality of life of dialysis patients with renal insufficiency.

Authors:  Marta Dąbrowska-Bender; Grażyna Dykowska; Wioletta Żuk; Magdalena Milewska; Anna Staniszewska
Journal:  Patient Prefer Adherence       Date:  2018-04-19       Impact factor: 2.711

10.  Prognostic importance and determinants of uremic pruritus in patients receiving peritoneal dialysis: A prospective cohort study.

Authors:  Hon-Yen Wu; Jenq-Wen Huang; Wan-Chuan Tsai; Yu-Sen Peng; Hung-Yuan Chen; Ju-Yeh Yang; Shih-Ping Hsu; Mei-Fen Pai; Mei-Ju Ko; Kuan-Yu Hung; Hsien-Ching Chiu
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

View more
  10 in total

1.  Prevalence of pruritus associated with hemodialysis and its association with sleep quality among hemodialysis patients: a multicenter study.

Authors:  Mefleh Daraghmeh; Montaser Badran; Ahmad Janajreh; Mohanad Hassan; Adham Abu Taha; Amer A Koni; Sa'ed H Zyoud
Journal:  BMC Nephrol       Date:  2022-06-17       Impact factor: 2.585

2.  Relationship Between Depression and Quality of Life Among Vitiligo Patients: A Self-assessment Questionnaire-based Study.

Authors:  Narumol Silpa-Archa; Chutipon Pruksaeakanan; Nattha Angkoolpakdeekul; Chayada Chaiyabutr; Kanokvalai Kulthanan; Woraphat Ratta-Apha; Chanisada Wongpraparut
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-08-04

3.  Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients.

Authors:  Nidhi Sukul; Angelo Karaboyas; Philipp A Csomor; Thilo Schaufler; Warren Wen; Frédérique Menzaghi; Hugh C Rayner; Takeshi Hasegawa; Issa Al Salmi; Saeed M G Al-Ghamdi; Fitsum Guebre-Egziabher; Pablo-Antonio Ureña-Torres; Ronald L Pisoni
Journal:  Kidney Med       Date:  2020-11-21

Review 4.  Novel approach to unpleasant symptom clusters surrounding pruritus in patients with chronic kidney disease and on dialysis therapy.

Authors:  Rebecca S Ahdoot; Kamyar Kalantar-Zadeh; James O Burton; Mark B Lockwood
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-01-01       Impact factor: 3.416

5.  The relationship between chronic kidney disease-associated pruritus and health-related quality of life: a systematic review.

Authors:  Edith Poku; Sue Harnan; Gill Rooney; Marrissa Martyn-St James; Mónica Hernández-Alava; Thilo Schaufler; Praveen Thokala; James Fotheringham
Journal:  Clin Kidney J       Date:  2021-11-09

Review 6.  Lettuce as an Effective Remedy in Uremic Pruritus: Review of the Literature Supplemented by an In Silico Study.

Authors:  Nazanin Zahra Sepehri; Mohammad Mahdi Parvizi; Sepideh Habibzadeh; Farhad Handjani
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-29       Impact factor: 2.629

7.  Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.

Authors:  Sarina Elmariah; Sarah Chisolm; Thomas Sciascia; Shawn G Kwatra
Journal:  JAAD Int       Date:  2022-04-20

8.  Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.

Authors:  Joel Topf; Thomas Wooldridge; Kieran McCafferty; Michael Schömig; Botond Csiky; Rafal Zwiech; Warren Wen; Sarbani Bhaduri; Catherine Munera; Rong Lin; Alia Jebara; Joshua Cirulli; Frédérique Menzaghi
Journal:  Kidney Med       Date:  2022-06-28

9.  Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.

Authors:  Steven Fishbane; Warren Wen; Catherine Munera; Rong Lin; Sukirti Bagal; Kieran McCafferty; Frédérique Menzaghi; Joana Goncalves
Journal:  Kidney Med       Date:  2022-06-28

10.  Effectiveness of montelukast for uremic pruritus in hemodialysis patients: A protocol for systematic review and meta-analysis.

Authors:  Chao-Qing Gao; Jia-Jun Zhou; Ya-Yin Tan; Chang-Jun Tong
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.